Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
 
Pipeline Monitor
AZ, Roche, Novartis, Janssen get good news
The European regulator has given a thumbs up to AZ's combined antibiotic Zavicefta and extended the uses of current drugs from other majors.
Working Life
How company restructures are impacting individuals
Job market changes precipitated by company restructures have had profound effects on individual behaviour, the latest Pharma in Focus survey shows.
Approvals Action
First competitor for Gilead HIV med
Apotex has registered the first competing brands for Gilead's $9m HIV treatment Viread.
Special Report
Pharma holds breath for budget
Tomorrow is Budget day but despite estimates that the deficit will grow substantially again, pharma is hopeful of a better outcome than last time.
Special Report
July PBAC reveals short but significant agenda
The next meeting of the PBAC has fewer submissions to decide on than has been the case recently but many concern significant innovative medicines.